🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Sanofi shares rise after French drugmaker ditches Horizon deal talks

Published 12-12-2022, 03:44 pm
© Reuters.
MRK
-
SASY
-
AMGN
-
AZN
-
PFE
-
JNJ
-
ALXN
-
ABMD
-
HZNP
-
PROR
-
IMGO
-

By Scott Kanowsky 

Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC (NASDAQ:HZNP).

Sanofi announced that it had ceased negotiations and dropped a potential offer for Horizon on Sunday, saying that the expected transaction price does not meet its "value creation criteria."

Analysts at Barclays said in a note that they expect Sanofi's decision will help boost its share price in the short term. The stock had previously slipped after Horizon revealed last month that Sanofi was in the running to acquire Horizon.

Sanofi's announcement, coupled with Johnson & Johnson's (NYSE:JNJ) choice to also scrap sales talks, leaves U.S. biotechnology giant Amgen Inc (NASDAQ:AMGN) in pole position to buy Horizon. In a report citing a source close to the negotiations, Bloomberg News said that Amgen has already agreed to a deal valuing Horizon at about $26 billion, or around $116.5 per Horizon share.

It would be Amgen's largest acquisition to date, and the biggest transaction in the pharmaceutical industry since AstraZeneca's (LON:AZN) $39B purchase of Alexion (NASDAQ:ALXN) in 2021.

Buying the Irish-headquartered Horizon would give Amgen a gateway to a number of lucrative treatments for rare autoimmune and inflammatory diseases, including the thyroid eye disease medicine Tepezza, which saw sales double over the last year. Revenue from this treatment is also expected to eventually top more than $4B once Horizon can secure the right to sell the drug in Europe and Japan.

Although deal activity has slowed in 2022, drugmakers have been harnessing big cash piles and a recent slide in healthcare stocks to renew their medicine pipelines through mergers and acquisitions. This year, Johnson & Johnson has inked a $16.6B deal for heart technology group Abiomed (NASDAQ:ABMD), while Merck (NS:PROR) & Co (NYSE:MRK) bought blood-cancer treatment developer Imago BioSciences (NASDAQ:IMGO) for $1.35B and Pfizer (NYSE:PFE) snapped up biotech Biohaven Pharmaceuticals for $11.6B.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.